ClinicalTrials.gg
CompletedNCT06135415TirbAKareUpdated Jun 30, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

A Phase 3 interventional study of Tirbanibulin and Vehicle ointment in Keratosis, Actinic, sponsored by Almirall, S.A.. Completed at 35 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Keratosis, Actinic by Almirall, S.A. — none open to participants now, 1 under way, none of them phase 3. Keratosis, Actinic · Almirall, S.A..

Enrollment
7th of 12
280 · median 307
Started
2023
with 1 other
Phase 3
7 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Keratosis, Actinic by Almirall, S.A., this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 14th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

None of the 14 studies in Keratosis, Actinic by Almirall, S.A. is open now. The open studies under Keratosis, Actinic, anywhere →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Keratosis, Actinic by Almirall, S.A. as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of tirbanibulin 10 milligrams per gram (mg/g) ointment when applied to a treatment field (TF) larger than 25 square centimeters (cm\^2) and up to 100 cm\^2 in adult participants with actinic keratosis (AK).

03

Conditions studied

  • Keratosis, Actinic

Keywords

  • Actinic Keratosis
  • Keratosis
  • Keratosis, Actinic
  • Precancerous condition
  • Neoplasms
  • Sun Damaged Skin
  • Actinic Keratoses
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants having a TF on the face or balding scalp (excluding lips, eyelids, and inside nostrils and ears) that contains >= 4 to less than or equal to (\<=) 12 clinically typical, visible, and discrete (non-confluent) AK lesions and measures more than 25 cm2 (example, one cheek) and up to approximately 100 cm2 (example, mid face).
  • Participants willing to avoid excessive sunlight or UV light exposure, including the use of tanning beds, to the face or scalp during the study.
  • Women of (WOCBP), that is, fertile, defined as a female in the life period from menarche and until becoming (no menses for 12 months without an alternative medical cause) or permanently sterile (with hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months prior to screening) must have a negative urine pregnancy test using a highly sensitive method at screening and on Day 1 prior to treatment administration, be using highly effective methods of for at least 30 days or 1 menstrual cycle, whichever is longer, and until at least 30 days or 1 menstrual period, whichever is longer, after the last dose of product, agree to have pregnancy tests while in the study and at the end of the study, and agree not to be egg (oocyte) donors while on study and until at least 30 days or 1 menstrual period, whichever is longer, after the last dose of investigational product.
  • Sexually active males with female partners who are WOCBP must agree to use two forms of contraception, one of which must be barrier contraception, from screening through 90 days after their last dose of study treatment. All non-sterile male participants must agree not to donate sperm or attempt conception from screening through 90 days following their last dose of study treatment.
  • Participants should have ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and provided written in accordance with institutional and regulatory guidelines.

Exclusion criteria

Exclusion Criteria:

  • Participants with clinically atypical and/or rapidly changing AK lesions in the TF; hyperkeratotic or hypertrophic lesions, recalcitrant disease (defined as failure to respond to cryosurgery on 2 previous occasions) and/or cutaneous horn; history of invasive SCC, Bowen's disease, BCC, or other malignant tumors in the TF; any other dermatological disease that causes difficulty with examination.
  • Location of the TF is on any location other than the face or balding scalp, within 5 centimeter (cm) of an incompletely healed wound, within 5 cm of a suspected BCC or other neoplasms, periorbital, lips, or nostrils.
  • Participants having a previous treatment with tirbanibulin 10 mg/g ointment.
  • Females who are pregnant or nursing or seeking to become pregnant.
  • Participants having intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required for a particular prohibited medication or therapy.
  • Participants with anticipated need for inpatient hospitalization or inpatient surgery from Day 1 to Day 113.
  • Participants with history of sensitivity and/or allergy to any of the ingredients in the study medication.
  • Participants with significant abnormalities on the medical history, physical examination (PE) findings, vital signs, clinical chemistry, or hematology results that in the judgment of the investigator may interfere with the interpretation of the results.
  • Participants with skin disease (example; atopic dermatitis, psoriasis, eczema) or condition (example; scarring, open wounds) that, in the opinion of the investigator, might interfere with the study conduct or evaluations, or which exposes the participant to unacceptable risk by study participation.
  • Participants with significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the investigator, would expose the participant to unacceptable risk by study participation.
  • Participants who have participated in an drug trial during which an investigational study medication was administered within 30 days or 5 half-lives of the investigational product, whichever is longer, before dosing in the current study.
  • Participant who is employee or a relative to an employee at the research site or the Sponsor.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    Tirbanibulin 10 mg/g

    Participants will apply tirbanibulin 10 mg/g ointment once daily for 5 consecutive days beginning on Day 1. All participants will be evaluated for efficacy, safety, and tolerability at Day 8, 15, 29, and 57. Participants who do not achieve complete clearance (CC) at Day 57 will receive a second 5-day course of the treatment. Participants receiving a second treatment course will also be evaluated for efficacy, safety, and tolerability at Day 64, 71, and 85.

    Drug: Tirbanibulin

  • Placebo comparator
    Vehicle ointment

    Participants will apply vehicle ointment once daily for 5 consecutive days beginning on Day 1. All participants will be evaluated for efficacy, safety, and tolerability at Day 8, 15, 29, and 57. Participants who do not achieve CC at Day 57 will receive a second 5-day course of the treatment. Participants receiving a second treatment course will also be evaluated for efficacy, safety, and tolerability at Day 64, 71, and 85.

    Other: Vehicle ointment

Interventions

  • Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.

    Also known as: Klisyri®

  • OtherVehicle ointment

    Participants will apply vehicle ointment topically on the face or balding scalp with AK.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Lesion Count at Day 57

    Percent change from baseline in the AK lesion count at Day 57 was reported.

    Time frame: Baseline, Day 57

Secondary outcomes

  1. Percentage of Participants With Partial Clearance at Day 57

    PC was defined as percentage of participants who achieved more than or equal to (\>=) 75 percent (%) clearance of AK lesions in the Treatment field (TF) on the face or scalp at Day 57.

    Time frame: At Day 57

  2. Percentage of Participants With Complete Clearance at Day 57

    Complete clearance was defined as percentage of participants who achieved 100% clearance (no AK lesions) in the TF on the face or scalp at Day 57.

    Time frame: At Day 57

  3. Percentage of Participants With Partial Clearance at Day 113

    Percentage of of participants with partial clearance at Day 113, defined as 100% clearance in the TF at Day 57 or, for participants receiving a second treatment course, ≥75% clearance at Day 113

    Time frame: At Day 113

  4. Percentage of Participants With Complete Clearance at Day 113

    Percentage of participants with complete clearance by Day 113, defined as 100% clearance in the TF at Day 57 or, for participants receiving a second treatment course, 100% clearance at Day 113

    Time frame: At Day 113

  5. Local Tolerability Signs Composite Score at Specific Timepoints

    Local Tolerability Signs Composite Score was assessed as the sum of six individual tolerability signs-erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. Each sign was graded on a scale from 0 (none) to 3 (severe) with a total score range of 0 to 18. The higher score indicates worst tolerability.

    Time frame: At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113

  6. Maximum Local Tolerability Signs Composite Score in Treatment Course

    Maximum local tolerability signs composite score was assessed as the sum of six individual tolerability signs-erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. Each sign was graded on a scale from 0 (none) to 3 (severe) with a total score range of 0 to 18. The higher score indicates worst tolerability.

    Time frame: At Week 1 to 8 (Day 57) and Week 8 to 16 (Day 113)

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAE of Special Interest

    An AE is defined as any untoward medical occurrence in a clinical trial participant, regardless of the administration of the IMP and its causal relationship to it. unfavorable and unintended medical occurrence during the participant's participation in the trial, including deterioration of a pre-existing medical condition, an abnormal value in a laboratory assessment, or an abnormal finding in the physical examination. TEAE- AEs that occurred after the first administration of the IMP, either tirbanibulin or vehicle, during the study. An SAE is any untoward medical occurrence that at any dose resulted in death; is life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in participant hospitalization; congenital anomaly/birth defect or otherwise considered medically important. AESIs included skin cancers \[including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma\] appearing within or outside the TF during the study.

    Time frame: From Baseline up to Day 113

07

Results

Posted Jun 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneVehicle OintmentTirbanibulin 10 mg/g
Started93187
Safety population93186
Completed74165
Not completed1922
Withdrew: Adverse event10
Withdrew: Death01
Withdrew: Lost to follow-up01
Withdrew: Physician decision03
Withdrew: Protocol deviation01
Withdrew: Withdrawal by subject1816

Outcome measures

PrimaryPercent Change From Baseline in Lesion Count at Day 57

Percent change from baseline in the AK lesion count at Day 57 was reported.

Time frame:
Baseline, Day 57
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Lesion Count at Day 57
Percent changeVehicle OintmentTirbanibulin 10 mg/g
Percent Change From Baseline in Lesion Count at Day 57-25.23 ± 3.96-64.15 ± 2.87
Statistical analysis
  • Vehicle Ointment vs Tirbanibulin 10 mg/g · ANCOVA · p = <0.001 · Least-squares (ls) mean difference: -38.92 · 95% CI -48.20 to -29.64LS means were obtained from an analysis of covariance (ANCOVA) model. For the ANCOVA model all participants are included, as missing values are imputed using baseline observation carried forward (BOCF).
SecondaryPercentage of Participants With Partial Clearance at Day 57

PC was defined as percentage of participants who achieved more than or equal to (\>=) 75 percent (%) clearance of AK lesions in the Treatment field (TF) on the face or scalp at Day 57.

Time frame:
At Day 57
Reported as:
Number · Percentage of participants
Percentage of Participants With Partial Clearance at Day 57
Percentage of participantsVehicle OintmentTirbanibulin 10 mg/g
Percentage of Participants With Partial Clearance at Day 5720.4 (13.49 to 29.72)58.8 (51.66 to 65.63)
Statistical analysis
  • Vehicle Ointment vs Tirbanibulin 10 mg/g · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 38.31 · 95% CI 27.82 to 48.81
SecondaryPercentage of Participants With Complete Clearance at Day 57

Complete clearance was defined as percentage of participants who achieved 100% clearance (no AK lesions) in the TF on the face or scalp at Day 57.

Time frame:
At Day 57
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Clearance at Day 57
Percentage of participantsVehicle OintmentTirbanibulin 10 mg/g
Percentage of Participants With Complete Clearance at Day 5715.1 (9.18 to 23.70)41.2 (34.37 to 48.34)
Statistical analysis
  • Vehicle Ointment vs Tirbanibulin 10 mg/g · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 26.24 · 95% CI 17.02 to 35.47
SecondaryPercentage of Participants With Partial Clearance at Day 113

Percentage of of participants with partial clearance at Day 113, defined as 100% clearance in the TF at Day 57 or, for participants receiving a second treatment course, ≥75% clearance at Day 113

Time frame:
At Day 113
Reported as:
Number · Percentage of participants
Percentage of Participants With Partial Clearance at Day 113
Percentage of participantsVehicle OintmentTirbanibulin 10 mg/g
Percentage of Participants With Partial Clearance at Day 11325.8 (18.00 to 35.53)65.2 (58.17 to 71.70)
Statistical analysis
  • Vehicle Ointment vs Tirbanibulin 10 mg/g · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 40.42 · 95% CI 29.99 to 50.84
SecondaryPercentage of Participants With Complete Clearance at Day 113

Percentage of participants with complete clearance by Day 113, defined as 100% clearance in the TF at Day 57 or, for participants receiving a second treatment course, 100% clearance at Day 113

Time frame:
At Day 113
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Clearance at Day 113
Percentage of participantsVehicle OintmentTirbanibulin 10 mg/g
Percentage of Participants With Complete Clearance at Day 11323.7 (16.17 to 33.23)56.1 (48.98 to 63.07)
Statistical analysis
  • Vehicle Ointment vs Tirbanibulin 10 mg/g · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 32.21 · 95% CI 21.84 to 42.58
SecondaryLocal Tolerability Signs Composite Score at Specific Timepoints

Local Tolerability Signs Composite Score was assessed as the sum of six individual tolerability signs-erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. Each sign was graded on a scale from 0 (none) to 3 (severe) with a total score range of 0 to 18. The higher score indicates worst tolerability.

Time frame:
At Day 1, 8, 15, 29, 57, 64, 71, 85, and 113
Reported as:
Mean · Score on a scale
Local Tolerability Signs Composite Score at Specific Timepoints
Score on a scaleVehicle OintmentTirbanibulin 10 mg/g
Baseline (Day 1)0.8 ± 1.680.9 ± 1.64
At Day 81.0 ± 1.474.0 ± 2.72
At Day 150.7 ± 1.261.8 ± 1.72
At Day 290.6 ± 1.230.6 ± 0.99
At Day 570.5 ± 1.210.4 ± 0.84
At Day 1130.3 ± 0.840.2 ± 0.75
SecondaryMaximum Local Tolerability Signs Composite Score in Treatment Course

Maximum local tolerability signs composite score was assessed as the sum of six individual tolerability signs-erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. Each sign was graded on a scale from 0 (none) to 3 (severe) with a total score range of 0 to 18. The higher score indicates worst tolerability.

Time frame:
At Week 1 to 8 (Day 57) and Week 8 to 16 (Day 113)
Reported as:
Mean · Score on a scale
Maximum Local Tolerability Signs Composite Score in Treatment Course
Score on a scaleVehicle OintmentTirbanibulin 10 mg/g
At Week 1 to 81.3 ± 1.804.1 ± 2.68
At Week 8 to 160.7 ± 0.932.9 ± 2.12
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAE of Special Interest

An AE is defined as any untoward medical occurrence in a clinical trial participant, regardless of the administration of the IMP and its causal relationship to it. unfavorable and unintended medical occurrence during the participant's participation in the trial, including deterioration of a pre-existing medical condition, an abnormal value in a laboratory assessment, or an abnormal finding in the physical examination. TEAE- AEs that occurred after the first administration of the IMP, either tirbanibulin or vehicle, during the study. An SAE is any untoward medical occurrence that at any dose resulted in death; is life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in participant hospitalization; congenital anomaly/birth defect or otherwise considered medically important. AESIs included skin cancers \[including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma\] appearing within or outside the TF during the study.

Time frame:
From Baseline up to Day 113
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAE of Special Interest
ParticipantsVehicle OintmentTirbanibulin 10 mg/g
TEAEs2879
Serious TEAEs29
TEAE of Special Interest22

Adverse events

Collected over Baseline up to Day 113. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Ointment0/93 (0%)2/93 (2.2%)28/93 (30.1%)
Tirbanibulin 10 mg/g1/186 (0.5%)9/186 (4.8%)79/186 (42.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventVehicle OintmentTirbanibulin 10 mg/g
OsteoarthritisMusculoskeletal and connective tissue disorders0/932/186
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/930/186
Renal colicRenal and urinary disorders1/930/186
Renal failureRenal and urinary disorders1/930/186
MelaenaGastrointestinal disorders0/931/186
Peritoneal adhesionsGastrointestinal disorders0/931/186
Multiple organ dysfunction syndromeGeneral disorders0/931/186
PneumoniaInfections and infestations0/931/186
Clavicle fractureInjury, poisoning and procedural complications0/931/186
Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/931/186
Most frequent other events
Showing 10 of 98
Most frequent other events
EventVehicle OintmentTirbanibulin 10 mg/g
ErythemaSkin and subcutaneous tissue disorders0/9327/186
Skin exfoliationSkin and subcutaneous tissue disorders0/938/186
Administration site exfoliationGeneral disorders0/936/186
PruritusSkin and subcutaneous tissue disorders2/936/186
Skin burning sensationSkin and subcutaneous tissue disorders0/936/186
HypertensionVascular disorders3/930/186
Actinic keratosisSkin and subcutaneous tissue disorders2/935/186
Application site pruritusGeneral disorders0/934/186
Application site exfoliationGeneral disorders0/934/186
NasopharyngitisInfections and infestations2/934/186

Baseline characteristics

Intention-To-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Vehicle OintmentTirbanibulin 10 mg/gTotal
Mean73.1 ± 9.3473.5 ± 9.0173.4 ± 9.11
Sex: Female, Male
Sex: Female, Male(Participants)Vehicle OintmentTirbanibulin 10 mg/gTotal
Female172845
Male76159235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vehicle OintmentTirbanibulin 10 mg/gTotal
Hispanic or Latino101323
Not Hispanic or Latino82166248
Unknown or Not Reported189
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vehicle OintmentTirbanibulin 10 mg/gTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White68136204
More than one race000
Unknown or Not Reported255176
08

Study locations

35 sites
  • Site 17
    Augsburg, Germany
  • Site 1
    Bad Bentheim, Germany
  • Site 3
    Bochum, Germany
  • Site 18
    Dresden, Germany
  • Site 2
    Hamburg, Germany
  • Site 5
    Hamburg, Germany
  • Site 4
    Mahlow, Germany
  • Site 6
    Wuppertal, Germany
  • Site 24
    Bari, Italy
  • Site 25
    Bologna, Italy
  • Site 19
    Brescia, Italy
  • Site 26
    Cagliari, Italy
  • Site 23
    Florence, Italy
  • Site 22
    Pisa, Italy
  • Site 27
    Reggio Emilia, Italy
  • Site 20
    Roma, Italy
  • Site 21
    Roma, Italy
  • Site 7
    Roma, Italy
  • Site 29
    Heemstede, Netherlands
  • Site 28
    Maastricht, Netherlands
  • Site 31
    Krakow, Poland
  • Site 30
    Ossy, Poland
  • Site 10
    Warsaw, Poland
  • Site 11
    Warsaw, Poland
  • Site 9
    Warsaw, Poland
  • Site 8
    Wroclaw, Poland
  • Site 12
    Barcelona, Spain
  • Site 14
    Barcelona, Spain
  • Site 34
    Barcelona, Spain
  • Site 33
    Granada, Spain
  • Site 13
    Madrid, Spain
  • Site 32
    Salamanca, Spain
  • Site 15
    Valencia, Spain
  • Site 35
    Valencia, Spain
  • Site 16
    Zaragoza, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Apr 2025, 16 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 18, 2023
StartActual
Dec 21, 2023
Primary completionActual
Apr 30, 2025
CompletionActual
Nov 25, 2025
Results first posted
Jun 30, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06135415
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Dec 21, 2023
Primary completion
Apr 30, 2025
Completion
Nov 25, 2025
Results posted
Jun 30, 2026
Last update
Jun 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirbanibulin

Start the discussion